Contact Us

Cymbalta
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you stopped taking this drug:

Date you started taking this drug:

Name(s) of all antidepressants taken:

Age of patient when antidepressant(s) prescribed:

What condition was this medication prescribed to treat?

Was suicide attempted after taking antidepressant(s)?

Did attempted suicide result in death?

Was hospitalization or institutionalization required after taking antidepressant(s)?

Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


FDA Criticizes Cymbalta's Medical Journal Ads

Nov 10, 2005 | Bloomberg

Eli Lilly & Co. failed to make the risks of its Cymbalta medicine clear enough in medical journal advertisements that promoted the drug to treat nerve pain caused by diabetes, U.S. regulators said.

In a letter to Lilly posted Wednesday on the U.S. Food and Drug Administration Web site, the agency said the company should stop running the ads. David Shaffer, a Lilly spokesman, said Wednesday in a telephone interview that the ads appeared in the 2004 fourth quarter and the 2005 first quarter and won't be run again.

The FDA said the ads are considered Cymbalta promotion even though their main panels don't mention the drug. Cymbalta, also used as an antidepressant, has risks that include dementia if used with older antidepressants known as monoamine oxidase inhibitors. It also can spur allergic reactions, the FDA said.


Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo